Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?

Yusuke Kobayashi, Kouji Banno, Haruko Kunitomi, Shimpei Nagai, Takayuki Takahashi, Mayuka Anko, Moito Iijima, Takashi Takeda, Yusuke Matoba, Kanako Nakamura, Kosuke Tsuji, Eiichiro Tominaga, Daisuke Aoki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institutions. Thus, there is an urgent need for researchers to be actively involved in investigator-initiated clinical trials.

Original languageEnglish
Pages (from-to)562-567
Number of pages6
JournalEuropean journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
Volume28
Issue number6
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Drug Repositioning
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmaceutical Preparations
Neoplasms
Molecular Mechanisms of Pharmacological Action
Research Personnel
Mevalonic Acid
Drug Costs
Endometrial Neoplasms
Dyslipidemias
Uterine Cervical Neoplasms
Health Care Costs
Ovarian Neoplasms
Coronary Disease
Cardiac Arrhythmias
Epidemiologic Studies
Colorectal Neoplasms
Prostatic Neoplasms
Heart Failure
Clinical Trials

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Cancer Research

Cite this

Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach? / Kobayashi, Yusuke; Banno, Kouji; Kunitomi, Haruko; Nagai, Shimpei; Takahashi, Takayuki; Anko, Mayuka; Iijima, Moito; Takeda, Takashi; Matoba, Yusuke; Nakamura, Kanako; Tsuji, Kosuke; Tominaga, Eiichiro; Aoki, Daisuke.

In: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), Vol. 28, No. 6, 01.11.2019, p. 562-567.

Research output: Contribution to journalArticle

@article{434d6fb2c75e4e5aa65ea2d05ee13051,
title = "Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?",
abstract = "Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institutions. Thus, there is an urgent need for researchers to be actively involved in investigator-initiated clinical trials.",
author = "Yusuke Kobayashi and Kouji Banno and Haruko Kunitomi and Shimpei Nagai and Takayuki Takahashi and Mayuka Anko and Moito Iijima and Takashi Takeda and Yusuke Matoba and Kanako Nakamura and Kosuke Tsuji and Eiichiro Tominaga and Daisuke Aoki",
year = "2019",
month = "11",
day = "1",
doi = "10.1097/CEJ.0000000000000497",
language = "English",
volume = "28",
pages = "562--567",
journal = "European Journal of Cancer Prevention",
issn = "0959-8278",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?

AU - Kobayashi, Yusuke

AU - Banno, Kouji

AU - Kunitomi, Haruko

AU - Nagai, Shimpei

AU - Takahashi, Takayuki

AU - Anko, Mayuka

AU - Iijima, Moito

AU - Takeda, Takashi

AU - Matoba, Yusuke

AU - Nakamura, Kanako

AU - Tsuji, Kosuke

AU - Tominaga, Eiichiro

AU - Aoki, Daisuke

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institutions. Thus, there is an urgent need for researchers to be actively involved in investigator-initiated clinical trials.

AB - Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institutions. Thus, there is an urgent need for researchers to be actively involved in investigator-initiated clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85063401959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063401959&partnerID=8YFLogxK

U2 - 10.1097/CEJ.0000000000000497

DO - 10.1097/CEJ.0000000000000497

M3 - Article

C2 - 30418231

AN - SCOPUS:85063401959

VL - 28

SP - 562

EP - 567

JO - European Journal of Cancer Prevention

JF - European Journal of Cancer Prevention

SN - 0959-8278

IS - 6

ER -